

Press release

October 22, 2012

Gothenburg, Sweden

Conference call interim report

Invitation to attend Vitrolife's conference call regarding presentation of the interim report for the period January – September, 2012. The presentation will be held in English.

Time: Thursday, November 1, 2012 at 10 a.m. CET.

Registration can preferably be done in advance under the following link:

<https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=185569>

or shortly before the conference starts on:

Sweden dial in number: +46 (0)8 505 201 10

UK dial in number: +44 (0)20 7162 0077

Conference name: Vitrolife, conference ID: 924075

Vitrolife participants:

Thomas Axelsson, CEO

Mikael Engblom, CFO

The press release for Vitrolife's interim report will be released at 08.30 a.m. CET on Thursday November 1, 2012.

Before the conference call, slides will be available at the company web page, www.vitrolife.com/en/Corporate/.

A recorded version of the conference call will be available for seven days on number +46 (0)8 505 203 33 (Sweden) or +44 (0)20 7031 4064 (UK), access code 924075.

Gothenburg, October 22, 2012

VITROLIFE AB (publ)

Contact:

Mikael Engblom, CFO, phone +46 (0)31 721 80 14

Vitrolife is a global biotechnology/medical device Group. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. There is also business to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are sold in ca 90 markets. The company is headquartered in Gothenburg, Sweden, and there are offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.